May 31 |
Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
|
May 31 |
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
|
May 31 |
How To Invest: Using Shorter-Term Moving Averages To Trade Stocks
|
May 31 |
European Commission approves Biogen’s QALSODY for ALS treatment
|
May 30 |
EU approves Biogen treatment for genetic form of ALS
|
May 30 |
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
|
May 29 |
Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
|
May 29 |
Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN
|
May 28 |
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
|
May 27 |
South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s
|